Difference between revisions of "Inherited coagulopathy"
Jump to navigation
Jump to search
m (→References) |
m |
||
| Line 1: | Line 1: | ||
| − | |||
| − | |||
| − | |||
{| class="wikitable" style="text-align:center; width:100%;" | {| class="wikitable" style="text-align:center; width:100%;" | ||
!colspan="4" align="center" style="color:white; font-size:125%; background-color:#31a354"|'''Section editors''' | !colspan="4" align="center" style="color:white; font-size:125%; background-color:#31a354"|'''Section editors''' | ||
| Line 35: | Line 32: | ||
|- | |- | ||
|[http://www.nejm.org/doi/full/10.1056/NEJMoa1703068 Oldenburg et al. 2017 (HAVEN 1)] | |[http://www.nejm.org/doi/full/10.1056/NEJMoa1703068 Oldenburg et al. 2017 (HAVEN 1)] | ||
| − | |style="background-color:#1a9851"|Phase III | + | |style="background-color:#1a9851"|Phase III (E) |
|No prophylaxis | |No prophylaxis | ||
|style="background-color:#1a9850"|Lower bleeding rate | |style="background-color:#1a9850"|Lower bleeding rate | ||
| Line 45: | Line 42: | ||
===References=== | ===References=== | ||
| − | # Oldenburg J, Mahlangu JN, Kim B, Schmitt C, Callaghan MU, Young G, Santagostino E, Kruse-Jarres R, Negrier C, Kessler C, Valente N, Asikanius E, Levy GG, Windyga J, Shima M. Emicizumab prophylaxis in hemophilia A with inhibitors. N Engl J Med. 2017 Aug 31;377(9):809-818. Epub 2017 Jul 10. [http://www.nejm.org/doi/full/10.1056/NEJMoa1703068 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/28691557 PubMed] | + | # '''HAVEN 1:''' Oldenburg J, Mahlangu JN, Kim B, Schmitt C, Callaghan MU, Young G, Santagostino E, Kruse-Jarres R, Negrier C, Kessler C, Valente N, Asikanius E, Levy GG, Windyga J, Shima M. Emicizumab prophylaxis in hemophilia A with inhibitors. N Engl J Med. 2017 Aug 31;377(9):809-818. Epub 2017 Jul 10. [http://www.nejm.org/doi/full/10.1056/NEJMoa1703068 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/28691557 PubMed] |
==Rituximab monotherapy {{#subobject:6d79c2|Regimen=1}}== | ==Rituximab monotherapy {{#subobject:6d79c2|Regimen=1}}== | ||
Revision as of 12:45, 9 August 2018
| Section editors | |||
|---|---|---|---|
 |
Shruti Chaturvedi, MBBS, MSCI Baltimore, MD |
 |
Benjamin Tillman, MD Nashville, TN |
3 regimens on this page
3 variants on this page
|
Factor VIII deficiency (Hemophilia A), replacement products
To be completed
Factor VIII deficiency (Hemophilia A), with inhibitors, all lines of therapy
Emicizumab monotherapy
| back to top |
Regimen
| Study | Evidence | Comparator | Efficacy |
|---|---|---|---|
| Oldenburg et al. 2017 (HAVEN 1) | Phase III (E) | No prophylaxis | Lower bleeding rate |
To be completed
Therapy
References
- HAVEN 1: Oldenburg J, Mahlangu JN, Kim B, Schmitt C, Callaghan MU, Young G, Santagostino E, Kruse-Jarres R, Negrier C, Kessler C, Valente N, Asikanius E, Levy GG, Windyga J, Shima M. Emicizumab prophylaxis in hemophilia A with inhibitors. N Engl J Med. 2017 Aug 31;377(9):809-818. Epub 2017 Jul 10. link to original article PubMed
Rituximab monotherapy
| back to top |
Regimen
| Study | Evidence |
|---|---|
| Leissinger et al. 2014 | Phase II |
Immunosuppressive therapy
- Rituximab (Rituxan) 375 mg/m2 IV once per day on days 1, 8, 15, 22
28-day course
References
- Kempton CL, Allen G, Hord J, Kruse-Jarres R, Pruthi RK, Walsh C, Young G, Soucie JM. Eradication of factor VIII inhibitors in patients with mild and moderate hemophilia A. Am J Hematol. 2012 Sep;87(9):933-6. link to PMC article does not contain protocol PubMed
- Leissinger C, Josephson CD, Granger S, Konkle BA, Kruse-Jarres R, Ragni MV, Journeycake JM, Valentino L, Key NS, Gill JC, McCrae KR, Neufeld EJ, Manno C, Raffini L, Saxena K, Torres M, Marder V, Bennett CM, Assmann SF. Rituximab for treatment of inhibitors in haemophilia A: a phase II study. Thromb Haemost. 2014 Sep 2;112(3):445-58. link to original article PubMed
Factor IX deficiency (Hemophilia B), all lines of therapy
To be completed